Please try another search
For the six months ended 30 June 2017, Biotech-igG AB revenues decreased 18% to SEK3.9M. Net loss increased from SEK1M to SEK2.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Personnel Expenses increase of 68% to SEK1.8M (expense), Other Operating Income decrease of 98% to SEK2K (income).
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 2.1 | 1.81 | 1.99 | 1.25 |
Gross Profit | -0.41 | -0.51 | -0.12 | -0.3 |
Operating Income | -1.54 | -1.17 | -0.65 | -0.73 |
Net Income | -1.52 | -1.17 | -0.65 | -0.73 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 9.26 | 9.95 | 10.86 | 2.91 |
Total Liabilities | 2.37 | 1.57 | 1.29 | 1.18 |
Total Equity | 6.88 | 8.38 | 9.56 | 1.74 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -2.19 | -0.92 | -2.22 | -1.84 |
Cash From Investing Activities | 0 | 0 | 0 | 0.03 |
Cash From Financing Activities | 0 | 0 | 8.48 | 0 |
Net Change in Cash | -2.19 | -0.92 | 6.26 | -1.8 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review